Form 4: Madrigal CCO Sells Shares for Tax, 10b5-1 Plan

Madrigal Pharmaceuticals' Chief Commercial Officer, Carole Huntsman, sold shares totaling 910 units on January 26, 2026, for tax obligations and under a pre-arranged 10b5-1 trading plan.

Summary

• Carole Huntsman, Chief Commercial Officer of Madrigal Pharmaceuticals, Inc. (MDGL), reported sales of common stock.
• The transactions occurred on January 26, 2026.
• A total of 340 shares were sold at a price of $492.42 per share to cover tax withholding obligations related to the vesting of restricted stock units. This sale was automatic and not at the discretion of the reporting person.
• An additional 570 shares were sold at a price of $494.59 per share pursuant to a Rule 10b5-1 trading plan.
• The Rule 10b5-1 trading plan was adopted by Carole Huntsman on November 5, 2024.
• Following these transactions, Carole Huntsman beneficially owns 9,122 shares of common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it involves insider selling, the reasons provided (tax withholding and a pre-arranged 10b5-1 plan) are routine and do not typically indicate a negative outlook on the company's future by the insider. The sales are not discretionary.

Negatives

• Insider selling, even for pre-planned or tax-related reasons, can sometimes be perceived negatively by the market, though these specific reasons mitigate the concern.

Risks

• While the sales are for specific, non-discretionary reasons (tax withholding) and a pre-arranged plan (10b5-1), a pattern of significant insider selling could potentially signal a lack of confidence in the company's future prospects, though this filing alone does not indicate such a pattern.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction filing (Form 4) common across all industries for publicly traded companies. It reflects a standard practice for executives to manage their equity compensation, often through pre-arranged trading plans or to cover tax obligations upon vesting of restricted stock units.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Commercial Officer is a routine event, unlikely to have a significant direct impact on shareholders, especially given the stated reasons for the sales. It represents a small portion of the insider's total holdings.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details routine insider stock sales by the Chief Commercial Officer for tax withholding obligations and under a pre-arranged 10b5-1 trading plan. These types of transactions are generally not indicative of a change in the company's fundamental outlook or performance. Therefore, based solely on this filing, a seasoned investor would likely maintain a 'hold' recommendation, awaiting more substantive operational or financial news to inform a change in investment thesis.

Keywords

Madrigal Pharmaceuticals, MDGL, Form 4, Insider Transaction, Stock Sale, 10b5-1 Plan, Carole Huntsman, Chief Commercial Officer, Tax Withholding